SCHEMBL15543281

SCHEMBL15543281

C/C(=N\OCc1ccc(C(F)(F)F)cc1)c1ccc(OCC(=O)N2CCOCC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 6/20 0.54
POLB P06746 1/20 0.51
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
HPGD P15428 3/20 0.49
NPC1 O15118 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
MDH1 P40925 1/20 0.48
MDH2 P40926 1/20 0.48
USP2 O75604 1/20 0.48
MAOB P27338 1/20 0.48
S1PR1 P21453 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15543283 1.00 FKBP1A (0.54) FKBP1APOLBALDH1A1SMN1; SMN2HPGD
SCHEMBL15543132 0.90 MDH1 (0.52) POLBSMN1; SMN2LMNAHTTKEAP1
SCHEMBL15543078 0.90 MDH1 (0.52) POLBSMN1; SMN2LMNAHTTKEAP1
SCHEMBL15543164 0.89 FKBP1A (0.55) FKBP1APOLBALDH1A1SMN1; SMN2HPGD
SCHEMBL16468364 0.89 FKBP1A (0.55) FKBP1APOLBALDH1A1SMN1; SMN2HPGD
SCHEMBL15543323 0.88 MDH1 (0.48) ALDH1A1MDH1MDH2USP2MAOB
SCHEMBL16468578 0.88 MDH1 (0.48) ALDH1A1MDH1MDH2USP2MAOB
SCHEMBL16468695 0.85 ALDH1A1 (0.53) FKBP1APOLBALDH1A1SMN1; SMN2HPGD
SCHEMBL15543208 0.85 ALDH1A1 (0.53) FKBP1APOLBALDH1A1SMN1; SMN2HPGD
SCHEMBL15543209 0.84 ALDH1A1 (0.54) FKBP1APOLBALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US claimed
EP-2864309-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES Cadila Healthcare Limited (IN) 2015-04-29 EP disclosed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US disclosed
WO-2014002105-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LIMITED (IN) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES PCSK9, HMGCR, CETP FKBP1A 1033/4885POLB 2808/4885ALDH1A1 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.